EVS REPORTS 2022 RESULTS
Publication on February 17, 2023, before market openingRegulated information – Press release annual resultsEVS
Globe Newswire17-02-2023, 12:37
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study 21-04-2023, 03:01